Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Expects Acurox Committee In April: What Are The Standards For Aversion-Based Abuse-Resistance?

This article was originally published in The Pink Sheet Daily

Executive Summary

King Pharmaceuticals expects up-or-down vote on formulation of immediate-release oxycodone with niacin. King will resubmit Acurox application after meeting.

You may also be interested in...



Drugs With Abuse Potential Should Recruit Two Types Of Patients For Trials

FDA is encouraging sponsors conducting clinical trials to assess the abuse potential of a new drug to enroll "drug-naive healthy subjects" as well as "experienced, recreational drug users who have a recent or current history of using a drug in the pharmaceutical class of the test drug.

Drugs With Abuse Potential Should Recruit Two Types Of Patients For Trials

FDA is encouraging sponsors conducting clinical trials to assess the abuse potential of a new drug to enroll "drug-naive healthy subjects" as well as "experienced, recreational drug users who have a recent or current history of using a drug in the pharmaceutical class of the test drug.

Regulatory Growing Pains: An Interview With King CEO Brian Markison (Part 2)

King Pharmaceuticals is in the center of a pivotal shift in the regulation of addictive pain therapies in the U.S. The company hopes to keep getting new products through FDA while helping to shape a class-wide opioid REMS. That is quite an agenda for 2010.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel